glp-1 cardiovascular outcomes 2025 news of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Cardiovascular Outcomes in Diabetes: New

As the pharmaceutical options expand and potentially become more accessible, the competitive landscape for natural GLP-1 support products will shift

It found people taking tirzepatide for type 2 diabetes lost as much as 12 pounds more than people taking a 1-milligram dose of semaglutide for 40 weeks

For a 180-pound (82 kg) person, that means roughly 100130 grams of protein per day

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

At this stage, the most responsible way to phrase the issue is: Retatrutide may become part of a more advanced generation of metabolic medications, but muscle preservation still depends on the full treatment plan including protein intake, resistance training, dose management, nutrition quality, sleep, hormones, and medical monitoring

Recent innovations, such as new subcutaneous injection devices and inhalable formulations, cater to patient preferences for convenience and needle-free options